Doh Lee, M.D., Ph.D., Jin Hyoung Kim, M.D., Suk Kyue Choi, M.D., Se Hoon Park, M.D.

Department of Ophthalmology, Ilsan Paik Hospital, Inje University College of Medicine, Gyeonggi, Korea

Authors have no financial interest

The Effect of Bevacizumab and Ranibizumab Injection

on Corneal Neovascularization

PURPOSE

To evaluate the effect of regression and treatment of subconjunctival and intralesional Bevacizumab

(AvastinⓇ)

and Ranibizumab (LucentisⓇ) injection on corneal neovascularization (CNV) resulting from different

ocular surface disorders

METHODS

Group I - Bevacizumab

(AvastinⓇ; Genentech, Inc., San Francisco, CA) - 1.25 mg/0.05cc injection only (n=5) under topical anesthesia

Group II - Ranibizumab (Lucentis Ⓡ ; Genentech, Inc., San Francisco, CA) - 0.5 mg/0.05cc injection only (n=5) under topical anesthesia

METHODS

Causes of NVs

Corneal herpes infection

Post-KP

Lipid degeneration

No. of eyes 6 2 2

Patients were followed up at 1, 7, 30 days after treatment.

Used Image J software (Wayne Rasband at the Research Services Branch, National Institute of Mental Health, Bethesda, MD) to analyze the vascularized corneal area.

• Charateristics of patients

Results - Area of CNV

Bevacizumab 1.25mg/0.05cc injection (Group I)

Pre injection Post injection (POD # 7)

< Post herpetic CNV with corneal opacity >

< Post KP CNV d/t Chemical burn >

Pre injection Post injection (POD # 7)

Results - Area of CNV

Bevacizumab 1.25mg/0.05cc injection (Group I)

Pre injection

Post injection (POD # 7)

< CNV d/t Lipid degeneration >

< CNV d/t corneal ulcer >

Pre injection

Post injection (POD # 7)Post injection (POD # 7)

Pre injection

< Post Pterygium OP. >

(By using Image J software)

Bevacizumab 1.25mg/0.05cc injection (Group I)

Results - Area of CNV

Results - Area of CNV

Ranibizumab 0.5mg/0.05cc injection (Group II)

Pre injection Post injection (POD # 7)

< Post KP CNV >

< CNV with corneal opacity d/t Lipid keratopathy >

Pre injection Post injection (POD # 7)

Results - Area of CNV

Ranibizumab 0.5mg/0.05cc injection (Group II)

Pre injection Post injection (POD # 7)

< Post herpetic CNV with corneal opacity >

Pre injection Post injection (POD # 7)

< Post herpetic CNV with corneal opacity >

(By using Image J software)

Ranibizumab 0.5mg/0.05cc injection (Group II)

Results - Area of CNV

Conclusions & Discussions Subconjunctival and intralesional Bevacizumab injection effectively regress CNV induced by various causes, whereas

there is no significant effect for CNS after Ranibizumab injection.

Bevacizumab injection were seems to be more effective to reduce CNV

than Ranibizumab injection.

Bevacizumab injection showed significant regression of CNV in short

period of time. After one month Bevacizumab injection, CNV had

tendency to recur and re-growth.

Subconjunctival and intralesional Bevacizumab injection could be considered a treatment option for

the CNVs.

Further research is needed to assess the potential duration, side – effects and minimal effective dose.

Conclusions & Discussions